Clinical Trial Search

Primary: Time to Death or Respiratory Intervention — NA months

Primary: PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up — 167; 747 Participants

Primary: Number of Participants With Post-operative Sensitivity Having VAS Score >3 — 14; 12; 6; 16 Participants — p=0.05

Primary: Participant Acceptance of Randomization Arm / Intervention — 8; 8; 10; 7 Participants

Primary: Change in Respectful Maternity Care — 21.8 score on a scale

Primary: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 — -1.32; -1.28; -1.21; -1.28 score on a scale…

Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg

Primary: Delayed-onset Muscle Soreness (DOMS) — 0.1; 0.1; 5; 4.1 units on a scale

Primary: Asparaginase Completion Rate — 63 Percentage of patients

Primary: Time to Bleeding Control After AAJT-S Device Application — 2 Minutes

Primary: Prevalence of Injuries in Amateur and Elite Mountain Bikers — 4.6; 3.5 Number of injuries

Primary: Difference in Weight Change Month 4 to Month 24 of the ADAPTIVE Group Compared to the STATIC Group, Controlling for Initial Weight Loss — 99.57; 100.22; 90.18; 90.59…

Primary: Proportion of Patients Transported With Spinal Immobilization — 1334; 813 Participants — p=0.0007

Primary: Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Number of Participants in Determining Messages — 1051; 1135; 0 Participants